Tyrosine kinase inhibitor-induced macrocytosis

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5225-5228

  Schallier, D ^a   Trullemans, F ^a   Fontaine, C ^a   Decoster, L ^a   De Greve, J ^a  

^a Oncologisch Centrum   (Belgium)

Author keywords

Hematological adverse event; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; BI 2992; ERLOTINIB; IMATINIB; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MEAN CORPUSCULAR VOLUME; MEGALOCYTOSIS; PRIORITY JOURNAL;

ANEMIA, MACROCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; HUMANS; INDOLES; NEOPLASM STAGING; NEOPLASMS; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIDINES; PYRIMIDINES; PYRROLES; QUINAZOLINES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 75149118201     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM and Michaelson MD: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524, 2006.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. New Engl J Med 356(2): 115-124, 2007.
3. Rini BI, Choueiri TK, Elson P, Khasawneh MK, Cotta C, Unnithan J, Wood L, Mekhail T, Garcia J, Dreicer R and Bukowski RM: Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 113(6): 1309-1314, 2008.
4. Aliberti S, Grignani G, Allione P, Vormola R, Bucci AS, Porrino G, Ricchiardi A, Carnevale Schianca F, Rota Scalabrini D and Aglietta M: Erythrocyte macrocytosis is a rather common apparently uneventful yet unexplained finding in GIST imatinib(I) chronic therapy. Proc ASCO 827S: 9045, 2005.
5. Kirkwood BR: Essentials of Medical Statistics. Blackwell Science, pp. 43-45, 2001.
6. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team: Adjuvant imatinib mesylate after resection of localised primary gastrointestinal stromal tumor: a randomized, double-blind, placebo-controlled trial. Lancet 373: 1097-1104, 2009.
7. Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J: GIST meta-analysis group (MetaGIST) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1640 patients. Proc ASCO 25: 10004, 2007.
8. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ and Borden EC: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the KIT receptor tyrosine kinase: S0033. J Clin Oncol 26(4): 626-632, 2008.
9. Gillessen S, Graf L, Korte W and Cerny T: Macrocytosis and cobalamin deficiency in patients treated with sunitinib. New Engl J Med 356: 2330-2331, 2007.
10. Billemont B, Izzedine H and Rixe O: Macrocytosis due to treatment with sunitinib. New Engl J Med 357: 1351-1352, 2007.
11. Chow LQ and Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25(7): 884-896, 2007.
12. Bugarski D, Krstic A, Mojsilovic S, Vlaski M, Petakov M, Jovcic G, Stojanovic N and Milenkovic P: Signaling pathways implicated in hematopoietic progenitor cell proliferation and differentiation. Exp Biol Med 232: 156-163, 2006.